LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

CareDx Inc

Gesloten

SectorGezondheidszorg

19.27 1.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.6

Max

19.51

Belangrijke statistieken

By Trading Economics

Inkomsten

-88M

-10M

Verkoop

-1.9M

85M

K/W

Sectorgemiddelde

16.92

50.291

EPS

0.1

Winstmarge

-12.225

Werknemers

644

EBITDA

-6.1M

-13M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+30.82% upside

Dividenden

By Dow Jones

Volgende Winsten

30 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

44M

1.1B

Vorige openingsprijs

18.17

Vorige sluitingsprijs

19.27

Nieuwssentiment

By Acuity

75%

25%

354 / 380 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 jun 2025, 23:49 UTC

Winsten

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 jun 2025, 22:19 UTC

Acquisities, Fusies, Overnames

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 jun 2025, 21:30 UTC

Winsten

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 jun 2025, 21:07 UTC

Winsten

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 jun 2025, 23:49 UTC

Marktinformatie

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 jun 2025, 23:39 UTC

Marktinformatie

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 jun 2025, 23:34 UTC

Acquisities, Fusies, Overnames

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 jun 2025, 23:33 UTC

Acquisities, Fusies, Overnames

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 jun 2025, 23:32 UTC

Acquisities, Fusies, Overnames

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 jun 2025, 23:32 UTC

Acquisities, Fusies, Overnames

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 jun 2025, 23:31 UTC

Acquisities, Fusies, Overnames

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 jun 2025, 23:31 UTC

Acquisities, Fusies, Overnames

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 jun 2025, 23:30 UTC

Acquisities, Fusies, Overnames

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 jun 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 jun 2025, 23:19 UTC

Acquisities, Fusies, Overnames

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 jun 2025, 22:06 UTC

Winsten

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 jun 2025, 21:15 UTC

Winsten

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 jun 2025, 21:07 UTC

Acquisities, Fusies, Overnames

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 jun 2025, 21:07 UTC

Acquisities, Fusies, Overnames

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 jun 2025, 21:07 UTC

Acquisities, Fusies, Overnames

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 jun 2025, 21:07 UTC

Winsten

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 jun 2025, 21:06 UTC

Acquisities, Fusies, Overnames

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 jun 2025, 21:06 UTC

Acquisities, Fusies, Overnames

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 jun 2025, 21:06 UTC

Marktinformatie

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 jun 2025, 21:05 UTC

Acquisities, Fusies, Overnames

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 jun 2025, 21:05 UTC

Acquisities, Fusies, Overnames

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 jun 2025, 20:52 UTC

Winsten

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 jun 2025, 20:51 UTC

Winsten

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 jun 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 jun 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

30.82% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25 USD  30.82%

Hoogste 30 USD

Laagste 19 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

2

Buy

2

Hold

1

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

354 / 380 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.